This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Acute Coronary Syndromes
+2

Effects of Intensive Antiplatelet Therapy for Patients With Clopidogrel Resistance After Coronary Stent Implantation

Sponsored by Shenyang Northern Hospital

About this trial

Last updated 13 years ago

Study ID

825004-5

Status

Completed

Type

Interventional

Phase

Phase 4

Placebo

No

Accepting

18-75 Years
35 to 75 Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 13 years ago

What is this trial about?

Clopidogrel resistance (CR) or low-responsiveness is associated with increased risk of ischemic events and can be detected by laboratory tests. This multicenter, randomized study is aimed to explore the efficacy and safety of intensive antiplatelet therapy (i.e. double clopidogrel maintenance dose and/or additional cilostazol)for patients with CR after coronary stenting.

What are the Participation Requirements?

Inclusion Criterial:

- aged 35 to 75 years

- acute coronary syndromes

- underwent successful coronary stent implantation

- informed consent

Exclusion Criteria:

- contraindications to antiplatelet therapy

- history of intracranial bleeding

- known bleeding disorders

- severe liver or kidney disease

- pregnancy

- left main coronary artery disease

- planned non cardiac surgery within 1 year

- end stage of other serious disease with life expectancy less than 1 year

- heart failure with NYHA grade 3 to 4